1) N. Ohtani-Fujita, T. Fujita, A. Aoike, N. E. Osifchin, P. D. Robbins, T. Sakai, CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene, Oncogene, 1993, 8, 1063-1067.

2) P. A. Jones, S. B. Baylin, The epigenomics of cancer, Cell, 2007, 128, 683-692.

3) Y. Kondo, J. P. Issa, Epigenetic changes in colorectal cancer, Cancer Metastasis Rev., 2004, 23, 29-39.

4) S. B. Baylin, J. E. Ohm, Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?, Nat. Rev. Cancer, 2006, 6, 107-116.

5) H. Cedar, Y. Bergman, Linking DNA methylation and histone modification : patterns and paradigms, Nat. Rev. Genet., 2009, 10, 295-304.

6) P. A. Jones, S. B. Baylin, The fundamental role of epigenetic events in cancer, Nat. Rev. Genet., 2002, 3, 415-428.

7) M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, J. P. Issa, CpG island methylator phenotype in colorectal cancer, Proc. Natl. Acad. Sci. USA, 1999, 96, 8681-8686.

8) F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L. G. Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S. B. Baylin, N. Ahuja, A. Viale, J. Massague, L. Norton, L. T. Vahdat, M. E. Moynahan, T. A. Chan, Breast cancer methylomes establish an epigenomic foundation for metastasis, Sci. Transl. Med., 2011, 3, 75ra25.

9) H. Noushmehr, D. J. Weisenberger, K. Diefes, H. S. Phillips, K. Pujara, B. P. Berman, F. Pan, C. E. Pelloski, E. P. Sulman, K. P. Bhat, R. G. Verhaak, K. A. Hoadley, D. N. Hayes, C. M. Perou, H. K. Schmidt, L. Ding, R. K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L. M. Cope, J. Buckley, J. G. Herman, S. B. Baylin, P. W. Laird, K. Aldape, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, 2010, 17, 510-522.

10) P. W. Laird, Thepower and the promise of DNA methylation markers, Nat. Rev. Cancer, 2003, 3, 253-266.

11) M. Esteller, J. Garcia-Foncillas, E. Andion, S. N. Goodman, O. F. Hidalgo, V. Vanaclocha, S. B. Baylin, J. G. Herman, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N. Engl. J. Med., 2000, 343, 1350-1354.

12) S. A. Belinsky, Gene-promoter hypermethylation as a biomarker in lung cancer, Nat. Rev. Cancer, 2004, 4, 707-717.

13) Y. Goto, K. Shinjo, Y. Kondo, L. Shen, M. Toyota, H. Suzuki, W. Gao, B. An, M. Fujii, H. Murakami, H. Osada, T. Taniguchi, N. Usami, M. Kondo, Y. Hasegawa, K. Shimokata, K. Matsuo, T. Hida, N. Fujimoto, T. Kishimoto, J. P. Issa, Y. Sekido, Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res., 2009, 69, 9073-9082.

14) Y. Okamoto, A. Sawaki, S. Ito, T. Nishia, T. Takahashi, M. Toyota, H. Suzuki, Y. Shinomura, I. Takeuchi, K. Shinjo, B. An, H. Ito, K. Yamao, M. Fujii, H. Murakami, H. Osada, H. Kataoka, T. Joh, Y. Sekido, Y. Kondo, Aberrant DNA methylation associated with aggressiveness of gastrointestinal stromal tumor, Gut, in press.

15) Y. Kondo, L. Shen, P. S. Yan, T. H. Huang, J. P. Issa, Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation, Proc. Natl. Acad. Sci. USA, 2004, 101, 7398-7403.

16) Y. Kondo, L. Shen, A. S. Cheng, S. Ahmed, Y. Boumber, C. Charo, T. Yamochi, T. Urano, K. Furukawa, B. Kwabi-Addo, D. L. Gold, Y. Sekido, T. H. Huang, J. P. Issa, Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation, Nat. Genet., 2008, 40, 741-750.

17) S. K. Singh, C. Hawkins, I. D. Clarke, J. A. Squire, J. Bayani, T. Hide, R. M. Henkelman, M. D. Cusimano, P. B. Dirks, Identification of human brain tumour initiating cells, Nature, 2004, 432, 396-401.

18) C. A. O'Brien, A. Pollett, S. Gallinger, J. E. Dick, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature, 2007, 445, 106-110.

19) P. B. Gupta, C. L. Chaffer, R. A. Weinberg, Cancerstem cells: mirage or reality?, Nat. Med., 2009, 15, 1010-1012.

20) C. B. Yoo, P. A. Jones, Epigenetic therapy of cancer: past, present and future, Nat. Rev. Drug. Discov. 2006, 5, 37-50.

21) L. Shen, H. Kantarjian, Y. Guo, E. Lin, J. Shan, X. Huang, D. Berry, S. Ahmed, W. Zhu, S. Pierce, Y. Kondo, Y. Oki, J. Jelinek, H. Saba, E. Estey, J. P. Issa, DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes, J. Clin. Oncol., 2010, 28, 605-613.

22) J. Chen, O. Odenike, J. D. Rowley, Leukaemogenesis: more than mutant genes, Nat. Rev. Cancer, 2010, 10, 23-36.

23) K. Kitamura, S. Hoshi, M. Koike, H. Kiyoi, H. Saito, T. Naoe, Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid, Br. J. Haematol., 2000, 108, 696-702.

24) S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, M. A. Fischbach, K. K. Wong, K. Brandstetter, B. Wittner, S. Ramaswamy, M. Classon, J. Settleman, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 2010, 141, 69-80.

25) J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, P. L. Lee, R. K. Karuturi, P. B. Tan, E. T. Liu, Q. Yu, Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells, Genes. Dev. 2007, 21, 1050-1063.

26) M. L. Suva, N. Riggi, M. Janiszewska, I. Radovanovic, P. Provero, J. C. Stehle, K. Baumer, M. A. Le Bitoux, D. Marino, L. Cironi, V. E. Marquez, V. Clement, I. Stamenkovic, EZH2 is essential for glioblastoma cancer stem cell maintenance, Cancer Res., 2009, 69, 9211-9218